This trial is active, not recruiting.

Conditions brain and central nervous system tumors, cognitive/functional effects, long-term effects secondary to cancer therapy in children, neurotoxicity, psychosocial effects of cancer and its treatment, radiation toxicity
Treatment donepezil
Sponsor Comprehensive Cancer Center of Wake Forest University
Collaborator National Cancer Institute (NCI)
Start date June 2006
End date February 2010
Trial size 14 participants
Trial identifier NCT00452868, CCCWFU-91305, CCCWFU-IRB-00000258, CDR0000537049, P30CA012197


RATIONALE: Donepezil may decrease the side effects caused by radiation therapy to the brain.

PURPOSE: This clinical trial is studying how well donepezil works in treating young patients with primary brain tumors previously treated with radiation therapy to the brain.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model single group assignment
Masking open label
Primary purpose supportive care
Donepezil 5 milligrams a day for 6 weeks
Donepezil 5 milligrams a day for 6 weeks

Primary Outcomes

Neurocognitive Function as Measured by the Neurocognitive Battery at 24 Weeks
time frame: 24 weeks

Eligibility Criteria

Male or female participants from 8 years up to 17 years old.

Inclusion Criteria: - Prior diagnosis of primary brain tumor - No type 2 neurofibromatosis - Underwent fractionated radiotherapy (≥ 23.4 Gy) with or without surgery or chemotherapy for the brain tumor at least 1 year ago - Karnofsky or Lansky performance status 70-100% - Fertile patients willing to use effective contraception - Baseline IQ ≥ 70 on Peabody Picture Vocabulary Test-3 - Stable weight within the past 6 months with no concern of weight loss - Vision aids and hearing aids must be used for all neuropsychologic/neurocognitive tests, If indicated - Able to speak English - More than 6 weeks since prior donepezil hydrochloride, EGb761, methylphenidate hydrochloride, other stimulants, or any other cognitive function-enhancing drug Exclusion Criteria: - Stereotactic radiosurgery as sole treatment - Evidence of disease progression by MRI - Pregnant or nursing - Attention-deficit/hyperactivity disorder before cancer diagnosis - Uncontrolled seizures or uncontrolled endocrinopathies - Uncontrolled comorbidities - Steroid dose greater than physiologic replacement (18-30 mg/m² hydrocortisone or equivalent) - Use of concurrent anticholinergic drugs

Additional Information

Official title A Pilot Study of Donepezil Hydrochloride in Pediatric Brain Tumor Survivors After Cranial Irradiation
Description OBJECTIVES: Primary - Determine the impact of donepezil hydrochloride on cognitive function in pediatric patients with primary brain tumors previously treated with cranial radiotherapy. Secondary - Assess health-related quality of life of patients treated with this drug. - Assess function and quality of life of the families of patients treated with this drug. - Determine the physiologic effects of radiotherapy on cerebrovascular hemodynamics in patients treated with this drug. - Determine the toxicity of donepezil hydrochloride in these patients. OUTLINE: This is a multicenter, pilot, open-label, controlled study. Patients receive oral donepezil hydrochloride once daily or once every other day for up to 24 weeks in the absence of disease progression or unacceptable toxicity. After completion of 6 weeks of study therapy, patients are evaluated for toxicity. Patients experiencing no adverse effects from treatment may continue receiving donepezil hydrochloride at a higher dose for 18 more weeks. Patients undergo measurement of cognitive function (by neurocognitive testing), behavioral adjustment and social competency (by parent-reported questionnaires), health-related quality of life (by child- and parent-reported questionnaires), and vascular dynamics (by transcranial Doppler ultrasound) at baseline and at weeks 12, 24, and 36. Family function and family quality of life are assessed at baseline and at week 24. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in January 2014.
Information provided to ClinicalTrials.gov by Comprehensive Cancer Center of Wake Forest University.